ArticleFrontiers in bioinformatics2026
Integrative analysis of YTHDC1 phosphoproteome unveils its phosphomodulatory network linked to splicing and tumorigenesis.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: YTH domain-containing protein 1 (YTHDC1) is a nuclear m6A reader with well-known roles in mRNA splicing, nuclear mRNA export, and DNA damage response. Although over 44 phosphosites, including those within the YTH domain, are detected in phosphoproteomic datasets, the phosphoregulatory mechanism that governs YTHDC1 function remains unknown. Methods: To delineate the phosphoregulatory landscape of YTHDC1, we conducted an integrative analysis of large-scale human phosphoproteomic datasets. The phosphosites were ranked according to their frequency of occurrence, and most recurrent sites were considered predominant. To explore their biological significance, we combined co-phosphorylation analysis with upstream kinase prediction and protein-interaction network mapping. Result: Three phosphosites, S308 and S146 located in the intrinsically disordered regions and S424 in the YTH domain, were identified as predominantly perturbed across datasets. Functional enrichment analysis of phosphosites in other proteins (PsOPs) co-regulated with these YTHDC1 phosphosites revealed their potential association with mRNA processing and splicing. Considering that no kinases are validated for these sites, phosphomotif-based analysis identified upstream kinases such as MAPK14, CDK7, AKT1, and PAK1. Annotation of phosphosites in these kinases co-regulated with the predominant YTHDC1 phosphosites demonstrated their association with kinase activity, reiterating their potential role as upstream kinases. The PsOPs, including these kinases, as well as many validated binary interactors associated with splicing-related functions, were enriched in the YTHDC1 phosphoregulatory network. Notably, 30 of the co-regulated PsOPs were enriched in pathways that are linked to carcinogenesis, and 4 were in DNA repair inhibition, thereby corroborating their possible role in phosphorylation-dependent signaling associated with cancer. Conclusion: Considering that targeted molecular biology experiments to explore the role of multiple phosphosites are challenging, our approach provides a suitable framework to infer phospho-site centric regulatory networks. Current findings suggest a putative role of YTHDC1 and its predominant phosphosites in RNA splicing and highlight its regulatory potential in tumor-associated signaling networks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.